best digital currency for investment- Top Overview

Jichuan Pharmaceutical Co., Ltd. and Dongke Pharmaceutical Co., Ltd., a wholly-owned subsidiary, have recently received the Drug Registration Certificate for Children Faropenem Sodium Granules and Cefezoxime Sodium for Injection approved and issued by National Medical Products Administration.The monkeypox vaccine with independent intellectual property rights in China was approved for clinical use. On December 10th, the monkeypox vaccine jointly developed by China Bio-Beijing Institute of Biological Products and China Center for Disease Control and Prevention received the approval notice of drug clinical trial issued by National Medical Products Administration, and it was registered and classified as Class 1.2 innovative vaccine. The vaccine is an innovative vaccine independently developed by scientists in China with completely independent intellectual property rights, which is expected to play an important role in the prevention and control of diseases caused by monkeypox virus in China. (China Biology)IEA Monthly Report: Despite the rising demand, the oil market will be fully supplied in 2025. The International Energy Agency (IEA) said on Thursday that although OPEC+extended the reduction of oil supply and the demand forecast was slightly higher than expected, the global oil market will be fully supplied in 2025. In its monthly oil market report, the agency said that its forecast of global oil demand growth in 2025 was raised from 990,000 barrels per day last month to 1.1 million barrels per day, "mainly from Asian countries, especially affected by China's recent stimulus measures".

Qianjin Pharmaceutical Co., Ltd.: The subsidiary company obtained the dapoxetine hydrochloride Pharmaceutical Registration Certificate, and Qianjin Pharmaceutical announced that Qianjin Xiangjiang Pharmaceutical Co., Ltd. received the dapoxetine hydrochloride Pharmaceutical Registration Certificate approved and issued by National Medical Products Administration. The medicine is suitable for the treatment of male premature ejaculation patients aged 18 to 64.Poly Development: Poly Group increased its holdings by 261 million yuan. According to the announcement of Poly Development, the actual controller of the company, Poly Group, has completed the plan to increase its holdings, and accumulated 27,980,100 A shares, accounting for 0.23% of the total share capital, with an increase of 261 million yuan. This increase plan will last for 12 months from December 12, 2023, and the increase amount will be no less than 250 million yuan and no more than 500 million yuan. After the completion of the increase, Poly Group directly holds about 3.03% of the company's shares, and the total shareholding ratio with its wholly-owned subsidiaries is 40.72%. The increase in holdings is in compliance with relevant laws and regulations, and Poly Group promises not to reduce its holdings within the statutory time limit.Deputy Prime Minister of Ukraine: We are ready to discuss the deployment of foreign troops in our own territory. On December 12, local time, the reporter of the General Desk learned that Ukrainian Deputy Prime Minister Stefani Hina said that Ukraine is ready to discuss the deployment of foreign troops in its own territory. It is reported that French President Macron and Polish Prime Minister Tusk plan to exchange views on the deployment of about 40,000 peacekeepers in Uzbekistan on the 12th. (CCTV News)

The second "Standards Week" of the National Network Security Standardization Technical Committee was held in Haikou in 2024, and the second "Standards Week" of the National Network Security Standardization Technical Committee (referred to as "Network Security Standardization Committee") was held in Haikou City, Hainan Province from December 8 to 11, 2024. Wang Jingtao, deputy director of the Central Network Information Office, deputy director of the National Network Information Office and chairman of the Network Security Standards Committee, pointed out that standards should help data security governance and supervision, speed up the development of standards such as data classification and classification protection requirements and compliance audit of personal information protection, and ensure the safe and orderly flow of data. It is necessary to lead the safe and orderly development of new technologies and applications such as artificial intelligence with standards and norms, accelerate the development and release of standards such as "Identification Method of Synthetic Content Generated by Artificial Intelligence", strengthen the research on relevant network security standards such as intelligent networked vehicles and autonomous driving, and effectively escort the safe development of emerging future industries.Huaxin Securities: China Unicom's operating income grew steadily and maintained its "buy" rating. Huaxin Securities Research Report pointed out that since the beginning of this year, China Unicom (600050.SH) has seen steady growth in operating income, rapid improvement in profitability, steady expansion of user scale and continuous consolidation of network foundation, laying a more solid foundation for high-quality development of enterprises. Communication and digital intelligence services are driven by two wheels, injecting vitality into the company's performance. Looking forward to the whole year, the company will adhere to the general tone of steady progress, promote the network to be new, technology to be new and service to be new, strive to achieve the performance goal of steady growth of operating income and double-digit growth of profits throughout the year, take greater steps in high-quality development, and accelerate the construction of a world-class science and technology service enterprise with global competitiveness. With the gradual expansion of user scale and the drive of digital transformation, the company will benefit from the continuous improvement of revenue and profit and maintain the "buy" investment rating.The monkeypox vaccine with independent intellectual property rights in China was approved for clinical use. On December 10th, the monkeypox vaccine jointly developed by China Bio-Beijing Institute of Biological Products and China Center for Disease Control and Prevention received the approval notice of drug clinical trial issued by National Medical Products Administration, and it was registered and classified as Class 1.2 innovative vaccine. The vaccine is an innovative vaccine independently developed by scientists in China with completely independent intellectual property rights, which is expected to play an important role in the prevention and control of diseases caused by monkeypox virus in China. (China Biology)